Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer

癌症 医学 免疫系统 癌症疫苗 肺癌 癌症研究 免疫学 免疫疗法 肿瘤科 内科学
作者
Joël Plumas,Anne Sibille,Ingel Demedts,Elvire Pons‐Tostivint,C. Van De Kerkhove,Sofie Derijcke,Willemijn S.M.E. Theelen,Bonne Biesma,Frank Borm,Els Wauters,Mike Collodoro,Kays Al Badawy,Camille Duchayne,Channa Debruyne,Beatrice DeVos,Benoît Colinet,Denis Moro‐Sibilot,M. Pérol,Eva-Lotte Buchmeier,Marcin Skrzypski,Kristof Cuppens,Johan Vansteenkiste
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 1182-1182
标识
DOI:10.1158/1538-7445.am2024-1182
摘要

Abstract We have developed an innovative cancer vaccine for the treatment of advanced NSCLC patients in combination with checkpoint inhibitors. This PDC*lung01 product based on an irradiated plasmacytoid dendritic cell line loaded with HLA-A*02:01 restricted peptides (NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE-A, MUC1, Survivin and Melan-A) is able to prime and expand peptide-specific CD8+ T cells in vitro and in vivo, and is synergistic with anti-Programmed Death (PD)-1 (Plumas et al, 2022; Hannani et al, 2023, NCT03970746). In study PDC-LUNG-101 with EudraCT number 2018-002382-19, PDC*lung01 is injected intravenously and subcutaneously for 6 times at two dose levels, 14 million, or 140 million cells in stage II/IIIA (cohort A1 & A2, monotherapy) or stage IV with TPS≥50% (cohort B1 & B2; in combination with pembrolizumab) patients. We report here the analysis of immune response of 3 cohorts (A1, A2, B1) of patients and the first 19 patients out of 42 (cohort B2) treated with high dose of PDC*lung01 in combination with Pembrolizumab at baseline and 3 timepoints post injection. Several circulating immune parameters have been evaluated at different times before and after vaccination using different assays we have developed: leukocyte count and determination of circulation peptide specific CD8+ T cells by flow cytometry using multimer tools without prior in vitro culture. The assay made on purified CD8+ T-cells allowed us to define a limit of quantification (LOQ) to accurately assess the fold changes of the cell expansion. In addition, tumor microenvironment (TME) was analyzed by multiplex fluorescence immunochemistry. The data of 42 patients for who an immune response has been evaluated (cohorts A and B) will be presented. No major changes in circulating main lymphocyte frequencies (B cells, NK cells, CD4+, CD8+, or Treg T cells) were observed during treatment. In addition, no major cell activation (CD25+, CD54, or DR+) was noted. In contrast, in a significant number of patients, PDC*lung01 induced circulating peptide-specific CD8+ T cell expansion in all 4 cohorts at different levels and time points against at least one out of seven peptides used. The percentages of patients for who an expansion of antigen-specific T-cell were observed were 50%, 64%, 66.7% and 68.4% in A1, A2, B1 and B2 cohorts respectively. The intensity of the immune response was proportional to the dose of PDC*lung01 and to the combination with pembrolizumab. When possible, total and peptide-specific CD8+ T cells were sorted for analysis of TCR repertoire, illustrating the modelling and dynamics of the immune response. The TME features will also be illustrated. To conclude, treatment with PDC*lung01 induces an anti-tumor immune response in a significant number of patients which appears to be enhanced by the combination with pembrolizumab. Citation Format: Joel Plumas, Anne Sibille, Ingel Demedts, Elvire Pons-Tostivint, Charlotte Van de Kerkhove, Sofie Derijcke, Willemijn Theelen, Bonne Biesma, Frank Borm, Els Wauters, Mike Collodoro, Kays Al Badawy, Camille Duchayne, Channa Debruyne, Beatrice Devos, Benoit Colinet, Denis Moro-Sibilot, Maurice Perol, Eva-Lotte Buchmeier, Marcin Skrzypski, Kristof Cuppens, Johan Vansteenkiste. PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1182.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
Tonnyjing应助耳朵儿歌采纳,获得10
5秒前
jialin完成签到,获得积分10
5秒前
6秒前
咖啡不加冰完成签到,获得积分10
6秒前
向晚发布了新的文献求助10
7秒前
希望天下0贩的0应助SmuA采纳,获得30
9秒前
赘婿应助帅比4采纳,获得10
9秒前
感动的一德完成签到,获得积分10
10秒前
12秒前
小萝卜完成签到,获得积分10
12秒前
davyean完成签到,获得积分10
13秒前
快乐小狗完成签到,获得积分10
13秒前
liuyingyun完成签到,获得积分10
14秒前
菜菜完成签到,获得积分20
15秒前
西瓜完成签到 ,获得积分10
15秒前
SSS完成签到 ,获得积分10
15秒前
17秒前
闪闪满天发布了新的文献求助10
17秒前
19秒前
bkagyin应助释然zc采纳,获得10
20秒前
水水完成签到 ,获得积分10
22秒前
祝君早日毕业完成签到,获得积分10
22秒前
22秒前
大肥羊发布了新的文献求助10
22秒前
开放的紫伊完成签到,获得积分10
23秒前
MT完成签到 ,获得积分10
23秒前
24秒前
24秒前
搜集达人应助身处人海采纳,获得10
24秒前
kuiuLinvk完成签到,获得积分10
24秒前
25秒前
发育不减肥完成签到,获得积分10
26秒前
zhangjingchang完成签到,获得积分10
26秒前
26秒前
xiaoxiao发布了新的文献求助10
28秒前
maomao完成签到,获得积分10
29秒前
29秒前
Ma发布了新的文献求助10
29秒前
JamesPei应助cccchen采纳,获得10
30秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
【本贴是提醒信息,请勿应助】请在求助之前详细阅读求助说明!!!! 20000
Evolution 5000
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
La Chine révolutionnaire d'aujourd'hui / Van Min, Kang Hsin 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3044554
求助须知:如何正确求助?哪些是违规求助? 2701739
关于积分的说明 7384800
捐赠科研通 2345718
什么是DOI,文献DOI怎么找? 1241583
科研通“疑难数据库(出版商)”最低求助积分说明 603979
版权声明 595503